JDRF has a plan for creating a world without type 1 diabetes (T1D) that focuses on driving promising therapies through the R&D pipeline and into the hands of individuals with T1D. A critical step in progress along the pipeline is known as the translational research phase. The goal of translational research is to move research […]
Although scientists are still working to determine what causes type 1 diabetes (T1D), research has given us insights into the disease process – knowledge that may eventually lead to potential therapies. One idea that has been explored over the past several years is that of beta cell stress and its connection to T1D, and a […]
We’re the plan to change the future type. JDRF research focuses on key therapies that hold significant promise in turning Type One into Type None, including: artificial pancreas, encapsulation, smart insulin, restoration, and prevention.
Last year JDRF took a number of significant actions to broaden the resources available in the T1D research and development space – three of them are highlighted here. Each of these will help speed progress towards our research goals across our portfolio of research objectives to develop and deliver novel T1D therapies to patients. In […]
A new JDRF-funded study will evaluate whether metformin—a drug commonly used to treat type 2 diabetes (T2D)—combined with standard insulin therapy could safely improve blood-glucose control in overweight children and adolescents with type 1 diabetes (T1D). For more than 50 years, metformin has proven safe and effective in helping to control blood-glucose levels in people […]
A clinical study published in PNAS provides further proof-of-concept that beta cell encapsulation holds real promise for making islet implantation a viable therapy for people with type 1 diabetes (T1D).
Type 1 diabetes (T1D) scientists have believed for some time that communities of bacterial microorganisms in the gut, which make up the microbiome, are in some way related to immune system defects and the autoimmune response that leads to T1D. Previous research has hypothesized that the diversity or abundance of specific bacteria within the microbiome […]
Last September, results from a JDRF-funded study were announced by Sansum Diabetes Research Institute and JDRF. This study addresses one of the key limitations of early artificial pancreas systems – the challenge of mealtime dosing of insulin. This is because insulin delivered through the skin by a pump or injections works much slower than insulin […]
Last September, Medtronic announced FDA approval of its MiniMed 530G with Enlite system (sold outside the United States as the Veo since 2009). JDRF applauded the U.S. Food and Drug Administration (FDA) for its commitment to ensuring patients in the United States can access insulin pumps that can temporarily stop insulin delivery once sensor glucose […]
JDRF-funded researchers across the globe are currently testing artificial pancreas systems. Some clinical trials are inpatient, in which participants stay overnight or for a few days in a hospital or research clinic, while others take place in an outpatient setting. In both cases, a medical team carefully monitors the daily life of each trial volunteer […]